MedTrace Logo

Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer

NCT03742713 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2020-12-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether CPC634 (CriPec® docetaxel) is effective in the treatment of patients with advanced epithelial ovarian cancer who are resistant to prior platinum-based chemotherapy

.

Conditions

Interventions

DRUG

CPC634 (CriPec® docetaxel)

Docetaxel containing CriPec® nanoparticles

Sponsors & Collaborators

  • Cristal Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jonathan Ledermann, MD,PhD · UCL Cancer Institute, London, UK

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-10-01
Primary Completion
2020-12-01
Completion
2020-12-01

Countries

  • Belgium
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03742713 on ClinicalTrials.gov